Clinical Trial Update: Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating bezafibrate added to UDCA in primary biliary cholangitis patients with non-optimal biochemical response, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Bezafibrate 200 mg (bezafibrate)
• Bezafibrate 400 mg (bezafibrate)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: BPC, Non Optimal Response to UDCA | Phase 3 | Status: RECRUITING